Alexander Greenhough's Outputs (3)

Hypoxia compromises the differentiation of human osteosarcoma cells to CAR-R, a hydroxylated derivative of lithocholic acid and potent agonist of the vitamin D receptor (2025)
Journal Article

The active metabolite of vitamin D3, calcitriol (1,25D), is widely recognised for its direct anti-proliferative and pro-differentiation effects. However, 1,25D is calcaemic, which restricts its clinical use for cancer treatment. Non-calcaemic agonist... Read More about Hypoxia compromises the differentiation of human osteosarcoma cells to CAR-R, a hydroxylated derivative of lithocholic acid and potent agonist of the vitamin D receptor.

Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways (2024)
Journal Article

Approximately 50% of poor prognosis neuroblastomas arise due to MYCN over-expression. We previously demonstrated that MYCN and PRMT5 proteins interact and PRMT5 knockdown led to apoptosis of MYCN amplified (MNA) neuroblastoma. Here we evaluate the hi... Read More about Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways.

Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3 (2024)
Journal Article

In a screen of over 200 novel pyrazole compounds, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl)ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a potential anticancer compound. GeGe-3 displays potent anti-angiogenic prope... Read More about Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3.